6:05 PM
 | 
Nov 06, 2012
 |  BC Extra  |  Company News

Novo Nordisk falls on insulin briefing docs

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) fell $14.35 to $145.27 in New York on Tuesday after FDA reviewers expressed concern with a cardiovascular safety signal for two of the company's insulin products under review for Type I and II diabetes. The reviewers said that a meta-analysis of CV events from 16 open-label trials showed that the risk of major adverse CV events (MACE) was "consistently higher" in pooled groups receiving Tresiba

Read the full 342 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >